About Us

Drew Fromkin is the Chief Executive Officer of Pulmovant and has served as Vant Portfolio Operating Partner for Roivant Sciences, Inc. (ROIV) since January 2021. He currently serves on the Board of Immunovant (IMVT) as Chair of the Compensation and Nominating and Governance committees and previously served as the Chief Executive Officer of Proteovant Therapeutics.

Mr. Fromkin is a highly accomplished global healthcare leader who over his 35-year career has led and served on the boards of public and private healthcare companies. Most notably, Mr. Fromkin served as President, Chief Executive Officer, and Director of Clinical Data, Inc. from 2006-2011. CLDA was sold to Forest Labs for a total consideration of $1.5 Billion. Mr. Fromkin has also served as Chairman and CEO of Tarveda Therapeutics, President and Chief Executive Officer of DoctorQuality, Inc. (sold to Quantros, Inc.), President, Chief Executive Officer and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. (MRK). From 2014 until 2016, Mr. Fromkin also served on the board of Regado Biosciences, Inc. which became Tobira Therapeutics, Inc. in 2015  (sold to Allergan for $1.7 Billion). Mr. Fromkin earned his B.A. in biology from Brandeis University.  

Ubaldo has 30 years of experience in the practice of clinical and academic medicine and clinical drug development with an intensive focus in the respiratory and inhaled medicines fields. Once entering the pharmaceutical industry and prior to joining Pulmovant, Ubaldo served as the Vice President for Late Phase Development at AstraZeneca where he oversaw the development of a broad range of respiratory medications including biologics and inhaled small molecules. He also was an integral part of the teams at AstraZeneca that developed and ultimately launched benralizumab and tezepelumab. More recently he served as the Vice President and Head for Clinical Development at Pulmocide where he oversaw Phase 2 and Phase 3 clinical trials for a novel inhaled antifungal.

Ubaldo completed his residency in internal medicine and fellowship in pulmonary and critical care medicine at Temple University Hospital in Philadelphia, and he was part of the Temple University Pulmonary Division faculty where he also served as Head of the Pulmonary Function and Exercise Laboratory and Head of the Pulmonary Rehabilitation Program. He earned his MD from the University Francisco Marroquin in Guatemala.

Joe Bishop serves as Chief Financial Officer of Pulmovant and is Senior Vice President at Roivant Sciences, where he oversees strategic and financial operations of biopharmaceutical companies (Vants). Before joining Roivant in 2018, he was Head of Equities at Pine River Capital Management, a $15 billion multi-strategy investment firm where he led global investment decisions across a team of multi-sector equity portfolios.

Mr. Bishop earned his B.S. in Mechanical Engineering from the Massachusetts Institute of Technology.

Jennifer Cormier serves as Senior Vice President, Clinical Operations for Pulmovant.  Jennifer has almost 20 years of pharmaceutical and medical device experience. She has led development stage drug programs from Phase 1 through Phase 4 post marketing approval studies across a range of therapeutic areas including rare genetic diseases, women’s health, Parkinson’s disease, diabetes/obesity, major depressive disorder, and hematologic oncology.  Prior to joining Pulmovant, Jennifer held senior clinical operations positions at Hemavant, PepGen, Relmada Therapeutics, and Sojournix.  Prior to Sojournix, she held various positions of increasing responsibilities in clinical operations, project management and Medical Affairs, leading global clinical programs and registry studies at Acorda Therapeutics, GI Dynamics and Shire. At Acorda, Jennifer led the Phase 3 Parkinson’s Disease Program for INBRIJA (levodopa inhalation powder), which was approved by the FDA and the EMA for the treatment of OFF episodes in Parkinson’s Disease.  She holds a B.S in Biology from University of Massachusetts Boston.

Carlos Sanmarco is the Senior Vice President - Program Leadership & Operations at Pulmovant, responsible for leading the mosliciguat program and overseeing the Program Management, CMC and business operations functions. Throughout his more than 20 years in drug development and clinical research at biotech and global pharma companies, Carlos has led research and development programs across a broad range of therapeutic areas, from candidate identification to launch. Prior to Pulmovant, Carlos was the Senior Vice President and Head of Program Management and Operations at Sonata Therapeutics (a Flagship Pioneering Company), and before that he served as the Vice President and Global Program Lead at Acceleron Pharma, responsible for overseeing the sotatercept program in pulmonary hypertension, from IND filing through Phase 3 completion, which led to the company acquisition by Merck & Co in 2021 for over $11 billion. At Acceleron Pharma, Carlos also coordinated and supervised the pulmonary therapeutic area strategy across all phases of development, including pre-clinical and early clinical development assets. Prior to Acceleron Pharma he served in various global leadership roles at Eli Lilly and Company, including Program Team Lead, Head of Clinical Operations and Medical Quality Lead. Carlos received his Pharm.D. and MBA from the University of Sao Paulo, Brazil.

Amy Yoney is a seasoned professional with over two decades of experience in the field of rare diseases. Ms. Yoney began her career as a clinical research manager under the distinguished Dr Robyn J Barst at Columbia University, where her primary role was overseeing over 20 clinical trials in the realm of Pulmonary Arterial Hypertension (PAH).

In 2005 Ms Yoney took a role with Encysive Pharmaceuticals  assuming the role of Global Medical Science Liaison, and then later assuming the role of Country Lead for BENELUX.

With her collective experiences Ms Yoney established a consulting company of her own, collaborating with renowned organizations such as Bayer, Novartis, GeNO, AiRES and Lung Biotech, showcasing her commitment to driving innovation in rare disease therapy. 

Ms Yoney’s expertise extended to Reata Pharmaceuticals in 2015 serving as a Sr Director MSL overseeing Phase 2 trials in Pulmonary Arterial Hypertension/Connective Tissue Disease (PAH/CTD) and PAH/Interstitial Lung Disease (PAH/ILD).

Brian Farrer is the Executive Director, Pharmaceutical Development at Pulmovant.  Prior to joining Pulmovant, Brian was Senior Director of Preclinical Development at Inhalon Biopharma.  Brian has over 20 years of pharmaceutical development experience at Inhalon, Liquidia Technologies and Merck Research Laboratories.  At Liquidia, he managed pharmaceutical development of the inhaled portfolio, which included Yutrepia.  He received his PhD in chemistry from the University of North Carolina-Chapel Hill, and his BA in Chemistry and Mathematics from Northwestern University in Chicago.